From Biomarkers to Treatment: The New Need-to-Know in Early Breast Cancer

Join our expert panel live in Chicago for the most up-to-date guidance on managing early-stage breast cancer. Learn how to optimally integrate new and emerging therapies, including targeted agents and immune checkpoint inhibitors, into individualized treatment plans while managing adverse events, promoting adherence, and optimizing patient experience. Register today!

To Register: On the Event Dates page, click a date/time, and then click the blue Register button in the upper right-hand corner. Once registered, you will receive a reminder email with a link to join in advance of the webinar.

Not an official event of the 2022 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, CancerLinQ®, or Conquer Cancer®, the ASCO Foundation.


  • Introduction
  • Targeted Therapies for HR+ EBC
  • Immunotherapy for Early TNBC
  • Clinical Challenges and Future Directions
  • Audience Question and Answer Session


Date / Time
Event Details


Program Director
Heather McArthur, MD, MPH

Associate Professor
Department of Medicine
Komen Distinguished Chair in Clinical Breast Cancer
Clinical Director Breast Cancer Program
Harold C. Simmons Comprehensive Cancer Center
UT Southwestern Medical Center
Dallas, Texas

Jennifer K. Litton, MD

Associate Professor of Medicine
Department of Breast Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas

Rita Nanda, MD

Associate Professor of Medicine
Breast Oncology
Section of Hematology/Oncology
Department of Medicine
The University of Chicago
Chicago, Illinois

Goal Statement
The goal of this activity is to improve the knowledge, confidence, and competence of learners to select and integrate new and emerging therapies into individualized treatment plans for early-stage breast cancer.

Target Audience
This program is intended for medical oncologists, pathologists, and other healthcare professionals who care for patients with breast cancer.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Apply guidelines and expert recommendations for germline BRCA testing in patients with early-stage breast cancer
  • Develop genetic testing and risk assessment strategies that incorporate expert guidance to identify all patient subgroups with EBC at high risk for recurrence
  • Discuss with patients how their risk of progression affects prognosis and therapeutic planning
  • Identify patients with EBC most likely to benefit from recently approved neoadjuvant/adjuvant targeted or immunotherapy agents
  • Plan adjuvant therapy using PARP inhibitor, immune checkpoint inhibitor, and/or CDK4/6 inhibitors for select patients with EBC
  • Manage treatment-related adverse events in the early-stage breast cancer setting associated with new treatment options to improve adherence, improve patient experience and optimize outcomes


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Designation of Credit

CCO designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.